Skip to main content
OpenTrials
Completed

NCT Number: NCT01047202

Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants

A single center, observer-masked, randomized clinical trial is to be conducted in 6-35 months infants to evaluate the safety and immunogenicity of Sinovac's influenza A/H1N1 Vaccine (PANFLU.1).

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–35 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

GuangXi Center for Diseases Control and Prevention

Guilin, Guangxi, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male or female aged between 6 and 35 months
  • Full-term birth, birth weight 2,500 grams or more
  • provided birth certification or vaccination card Parent(s) or legal guardian(s) are able to understand and sign the informed consent

Exclusion criteria

  • Cases, cured cases and close contact of influenza A (H1N1) virus
  • Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
  • Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  • Symptoms of acute infection within a week
  • Autoimmune disease or immunodeficiency
  • Congenital malformation, developmental disorders or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders)
  • Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
  • Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  • History or family history of convulsions, epilepsy, brain disease and psychiatric
  • Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
  • Guillain-Barre Syndrome
  • Administration of 2009-2010 seasonal vaccine
  • History of any blood products within 3 months
  • Administration of any other investigational research agents within 30 days
  • Administration of any live attenuated vaccine within 30 days
  • Administration of subunit or inactivated vaccines within 14 days
  • Be receiving anti-TB prophylaxis or therapy currently
  • Axillary temperature > 37.0 centigrade at the time of dosing
  • Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Treatment and study plan

Pandemic influenza A/H1N1 vaccine

Biological

Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose

Seasonal trivalent vaccine

Biological

Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose

Primary outcomes

  1. Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in infants

    Time frame: 3 months

Secondary outcomes

  1. Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in infants

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Sinovac Biotech Co., Ltd

Industry

Registry information

Official study title

A Blinded, Randomized and Controlled Clinical Trial With Influenza A/H1N1 Split-virion Vaccine in 6 to 35 Months Infants

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jan 12, 2010
Registry last updated
Mar 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.